Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated September 14, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader authorization to repurchase up to DKK 15 billion in shares over a 12-month period beginning February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Limit: Up to DKK 15 billion (total programme starting Feb 4, 2026).
- Specific Tranche Limit: Up to DKK 11,200,000,010.45 for the period May 6, 2026, to February 1, 2027.
- Total Repurchased (since Feb 4, 2026): 33,084,179 B shares.
- Average Purchase Price (since Feb 4, 2026): DKK 281.89 per B share.
- Total Transaction Value (since Feb 4, 2026): DKK 9,326,186,478.
- Treasury Shares Held: 47,124,876 B shares (1.1% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the previous announcement on September 7, 2026, the company executed five additional transactions between September 7 and September 11, 2026. These transactions involved the purchase of 1,050,000 B shares at an average price ranging from DKK 278.62 to DKK 297.98, totaling approximately DKK 304.4 million. Consequently, the accumulated number of shares repurchased under the specific May 6 programme increased to 18,325,000 shares with a total value of DKK 5,526,186,488.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the total limit of DKK 15 billion during the 12-month period commencing February 4, 2026. The company operates under the "Safe Harbour Rules" of the EU Market Abuse Regulation. No specific operational risks, contingencies, or unusual items regarding business performance were disclosed in this filing; the focus remains strictly on the execution of the capital return programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total repurchase authorization (approx. DKK 5.67 billion remaining as of Sept 11, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 281.89.
- Review the full transaction history on novonordisk.com for granular daily execution data.
- Monitor the timeline for the programme's conclusion on February 1, 2027, for the specific tranche and February 4, 2027, for the overall programme.